Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts
نویسندگان
چکیده
منابع مشابه
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 4...
متن کاملTreatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
The transition of patients with ≥20% <30% bone marrow (BM) blast from the FAB category of myelodysplasia to the family of acute myeloid leukemia (AML) according to the recent WHO classification has not resolved the argument as to whether the natural history and responsiveness to therapy of these diseases is comparable to that of AML with > 30% BM blast. These controversies are even more manifes...
متن کاملTenupodia formation by blasts in bone marrow aspirate smears from a patient with acute monoblastic leukemia.
Primitive hematopoietic myeloid cells have been observed to extend long, thin pseudopodia. Recently, Francis et al1 reported the presence of 2 new morphologic types of pseudopodia, tenupodia and magnupodia, formed by the human myeloid progenitor cell line KG1a and human CD341 cells from fetal liver, umbilical cord blood, adult bone marrow, and mobilized (using either granulocyte-macrophage colo...
متن کاملCorrelation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes
Dear Editor, Determination of the percentage of blasts in the bone marrow (BM) is one of the critical factors in diagnosing MDS. Flow cytometry (FCM) of BM cells has been introduced as an important co-criterion for diagnosing MDS [1-3]. However, FCM has not been well accepted because of the lack of consensus of the criteria to define a phenotypic myeloblast and the appropriate denominator for c...
متن کاملara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
It has been unclear whether regimens containing topotecan 1 ara-C (TA) or fludarabine 1 ara-C (FA) 6 idarubicin are superior to regimens containing idarubicin 1 ara-C (IA) without either fludarabine or topotecan for treatment of newly diagnosed acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or RAEB. Of 1279 patients treated here for these diagnose...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Modern Pathology
سال: 2016
ISSN: 0893-3952,1530-0285
DOI: 10.1038/modpathol.2016.118